Drugs / RIG-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07488897 | Feb 2026 → Feb 2027 expected | acute asthma | RIGImmune Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | RIGImmune Inc. | Results RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024 rigimmune.com ↗
RIG-101 significantly reduced viral load in vivo and in vitro, as well as strongly induced CXCL10, a surrogate marker of antiviral interferon production in vitro and prevented neutrophil accumulation, a sign of inflammation, in the nasal lavage in vivo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | RIGImmune Inc. | RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024 rigimmune.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIG-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488897 ↗ |
| Route | Intranasal | “escalating intranasal administrations of RIG-101” NCT07488897 ↗ |